Psychiatric Quarterly

, Volume 80, Issue 3, pp 131–141 | Cite as

Effects of Antidepressant Treatment on Antiretroviral Regimen Adherence Among Depressed HIV-Infected Patients

Original Paper


This study examined whether the relationship between HAART medication adherence and antidepressant treatment varied with HAART regimen complexity. The analysis included 1,192 respondents to the HIV Cost and Service Utilization Study (HCSUS) who were taking HAART. Self-reported past-week HAART adherence, antidepressant use, current mental health status, and an aggregate measure of regimen complexity were used in the analysis. Regression models with interactions between antidepressant treatment of mental health problems, poor emotional well-being or depressive symptoms, and medication complexity were estimated to assess differential associations with adherence. Irrespective of antidepressant treatment, poor mental health status was negatively associated with HAART medication adherence. However, only untreated higher depressive symptoms were strongly associated with maladherence to HAART medication (OR = 0.72 at P < 0.05). Medication complexity was strongly associated with maladherence to HAART medication (OR = 0.96 with P < 0.05) in the model including emotional well-being; and weakly associated with maladherence (OR = 0.97 and P < 0.07) in the model including depressive and/or anxiety symptoms. However, as HAART medication complexity increased, adherence was higher among individuals with poorer mental health but using antidepressants compared to those with better mental health (OR = 1.09 with P < 0.05 in the model including emotional well-being; OR = 1.09 and P < 0.05 in the model including depressive and/or anxiety symptoms), and compared to those with poorer mental health but not using antidepressants (OR = 1.09, P = 0.08 in the model including emotional well-being, and OR = 1.12, P < 0.05 in model including depressive and/or anxiety symptoms). In conclusion, while individuals with poorer mental health generally have poor HAART adherence, their adherence improved with the use of antidepressants as the HAART complexity increased.


Medication adherence HIV drugs Antidepressants 


  1. 1.
    Bangsberg DR: Less than 95% adherence to nonnucleoside reverse transcriptase inhibitor therapy can lead to viral suppression. Clinical Infectious Disease 43:939–941, 2006. doi: 10.1086/507526 CrossRefGoogle Scholar
  2. 2.
    Osterberg L, Blaschke T: Adherence to medication. New England Journal of Medicine 353:487–497, 2005. doi: 10.1056/NEJMra050100 PubMedCrossRefGoogle Scholar
  3. 3.
    Chesney M: Adherence to HAART regimens. AIDS Patient Care 17:169–177, 2003. doi: 10.1089/108729103321619773 CrossRefGoogle Scholar
  4. 4.
    Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine 133(1):21–30, 2000PubMedGoogle Scholar
  5. 5.
    Ciesla JA, Roberts JE: Meta-analysis of the relationship between HIV infection and risk for depressive disorders. American Journal of Psychiatry 158:725–730, 2001. doi: 10.1176/appi.ajp.158.5.725 PubMedCrossRefGoogle Scholar
  6. 6.
    Mugavero M, Ostermann J, Whetten K, et al.: Barriers to antiretroviral adherence: The importance of depression, abuse, and other traumatic events. AIDS Patient Care STDs 20:418–428, 2006. doi: 10.1089/apc.2006.20.418 PubMedCrossRefGoogle Scholar
  7. 7.
    Ammassari A, Antinori A, Aloisi MS, et al.: Depressive symptoms neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics 45:394–402, 2004. doi: 10.1176/appi.psy.45.5.394 PubMedCrossRefGoogle Scholar
  8. 8.
    Castaneda AE, Suvisaari J, Marttunen M, Perala J, Saarni SI, et al.: Cognitive functioning in a population-based sample of young adults with a history of non-psychotic unipolar depressive disorders without psychiatric comorbidity. Journal of Affective Disorders 110(1–2):36–45, 2008. doi: 10.1016/j.jad.2007.12.239 PubMedCrossRefGoogle Scholar
  9. 9.
    Paleacu D, Shutzman A, Giladi N, Herman T, Simon ES, et al.: Effects of pharmacological therapy on gait and congnitive functions in depressed patients. Clinical Neuropharmacology 30(2):63–71, 2007. doi: 10.1097/01.wnf.0000240949.41691.95 PubMedCrossRefGoogle Scholar
  10. 10.
    Austin M-P, Mitchell P, Goodwin GM: Congnitive deficits in depression. British Journal of Psychiatry 178:200–206, 2001. doi: 10.1192/bjp.178.3.200 PubMedCrossRefGoogle Scholar
  11. 11.
    Hinkin CH, Hardy DH, Mason KI, Castellon SA, Durvasula RS, Lam MN, et al.: Medication adherence in HIV-infected adults: Effect of patient age, cognitive status, and substance abuse. AIDS 18(Suppl 1):S19–S25, 2004. doi: 10.1097/00002030-200401001-00004 PubMedGoogle Scholar
  12. 12.
    Waldrop-Valverde D, Ownby RL, Wilkie FL, Mack A, Kumar M, et al.: Neurocognitive aspects of medication adherence in HIV-positive injecting drug users. AIDS and Behavior 10(3):287–297, 2006. doi: 10.1007/s10461-005-9062-6 CrossRefGoogle Scholar
  13. 13.
    Chesney MA: HIV The elusive gold standard: Future perspectives for HIV adherence assessment and intervention. Journal of Acquired Immune Deficiency Syndromes 43(Suppl 1):S149–S155, 2006. doi: 10.1097/01.qai.0000243112.91293.26 CrossRefGoogle Scholar
  14. 14.
    Friedland GH: HIV medication adherence. The intersection of biomedicatl, behavioral, and social science research and clinical practice. Journal of Acquired Immune Deficiency Syndromes 43(Suppl 1):S3–S9, 2006CrossRefGoogle Scholar
  15. 15.
    Hinkin CH, Castellon SA, Durvasula RS, et al.: Medication adherence among HIV+adults. Neurology 59(12):1944–1950, 2002PubMedGoogle Scholar
  16. 16.
    Himelhoch S, Medoff DR: Efficacy of antidepressant medication among HIV-positive individuals with depression: A systematic review and meta analysis. AIDS Patient Care and STDs 19(12):813–822, 2005. doi: 10.1089/apc.2005.19.813 PubMedCrossRefGoogle Scholar
  17. 17.
    Dalessandro M, Conti CM, Gambi F, Falasca K, Doyle R, et al.: Antidepressant therapy can improve adherence to antiretroviral regimens among HIV-infected and depressed patients. Journal of Clinincal Psychopharmacology 27(1):58–61, 2007. doi: 10.1097/JCP.0b013e31802f0dd1 CrossRefGoogle Scholar
  18. 18.
    Walkup J, Wei W, Sambamoorthi U, Crystal S: Antidepressant treatment and adherence to combination antiretroviral therapy among patients with AIDS and diagnosed depression. Pyschiatric Quarterly 79:43–53, 2008. doi: 10.1007/s11126-007-9055-x CrossRefGoogle Scholar
  19. 19.
    Horberg MA, Silverberg MJ, Hurley LB, Towner WJ, Klein DB, et al.: Effects of depression and selective serotonine reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. Journal of Aquired Immune Deficiency Syndrome 47(3):384–390, 2008CrossRefGoogle Scholar
  20. 20.
    Martin S, Wolters PL, Calabrese SK, Toledo-Tamula MA, Wood LV, et al.: The antiretroviral regimen complexity index: A novel method of quantifying regimen complexity. Journal of Acquired Immune Deficiency Syndromes 45(5):535–544, 2007. doi: 10.1097/QAI.0b013e31811ed1f1 CrossRefGoogle Scholar
  21. 21.
    Bozzette SA, Berry SH, Duan N, Frankel MR, Leibowitz AA, Lefkowitz D, et al.: The care of HIV-infected adults in the United States. HIV cost and services utilization study consortium. The New England Journal of Medicine 339(26):1897–1904. doi: 10.1056/NEJM199812243392606 PubMedCrossRefGoogle Scholar
  22. 22.
    Frankel MR, Shapiro MF, Duan N, Morton SC, Berry SH, Brown JA, et al.: National probability samples in studies of low-prevalence diseases. Part II: Designing and implementing the HIV cost and services utilization study sample. Health Services Research 34(5 Pt 1):969–992, 1999PubMedGoogle Scholar
  23. 23.
    Shapiro MF, Berk ML, Berry SH, Emmons CA, Athey LA, Hsia DC, et al.: National probability samples in studies of low-prevalence diseases. Part I: Perspectives and lessons from the HIV cost and services utilization study. Health Services Research 34(5 Pt 1):951–968, 1999PubMedGoogle Scholar
  24. 24.
    United States Department of Agriculture & United States Department of Health and Human Services: In: United States Department of Health and Human Services & United States Department of Agriculture (Eds.), Chapter 9—Alcoholic beverages. Dietary Guidelines for Americans. Washington, DC: US Government Printing Office pp. 43–46, 2005Google Scholar
  25. 25.
    National Institute of Alcohol Abuse and Alcoholism: NIAAA council approves definition of binge drinking [Electronic Version]. 2004; NIAAA Newsletter, 3. Retrieved October 16, 2007 from
  26. 26.
    Haubrich RH, Little SJ, Currier JS, Forthal DN, Kemper CA, Beall GN, et al.: The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS 13(9):1099–1107, 1999. doi: 10.1097/00002030-199906180-00014 PubMedCrossRefGoogle Scholar
  27. 27.
    Mannheimer S, Friedland G, Matts J, Child C, Chesney M: The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clinical Infectious Diseases 34(8):1115–1121, 2002. doi: 10.1086/339074 PubMedCrossRefGoogle Scholar
  28. 28.
    Palepu A, Tyndall MW, Joy R, Kerr T, Wood E, et al.: Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: The role of methadone maintenance therapy. Drug and Alcohol Dependence 84(2):188–194, 2006. doi: 10.1016/j.drugalcdep.2006.02.003 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.WestatRockvilleUSA
  2. 2.Agency for Healthcare Research and QualityRockvilleUSA

Personalised recommendations